Impact on Business Plans from Competitors with Greater Financial and Technological Resources
First written in FY2017. 4 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Many of these competitors have advantages over us in areas including technological capabilities, marketing capabilities and financial position, and may be able to produce and market competing pharmaceutical products with greater efficacy more efficiently.」
The risk of an impact on the business plan from competitors with greater financial, technological and marketing resources remains. - FY2022RestatedAnnual report
「Many of these competitors have advantages over us in areas including technological capabilities, marketing capabilities and financial position, and may be able to produce and market competing pharmaceutical products with greater efficacy more efficiently.」
The risk of an impact on the business plan from competitors with greater financial, technological and marketing resources remains. - FY2021RestatedAnnual report
「Many of these competitors have advantages over us in areas including technological capabilities, marketing capabilities and financial position, and may be able to produce and market competing pharmaceutical products with greater efficacy more efficiently.」
The risk of an impact on the business plan from competitors with greater financial, technological and marketing resources remains. - FY2020RestatedAnnual report
「Many of these competitors have advantages over us in areas including technological capabilities, marketing capabilities and financial position, and may be able to produce and market competing pharmaceutical products with greater efficacy more efficiently.」
The risk of an impact on the business plan from competitors with greater financial, technological and marketing resources remains. - FY2017First statedAnnual report
「Many of these competitors have advantages over us in areas including technological capabilities, marketing capabilities and financial position, and may be able to produce and market competing pharmaceutical products with greater efficacy more efficiently.」
Major pharmaceutical companies, biotechnology companies and universities have advantages in technological capabilities, marketing capabilities and financial resources, potentially affecting projected results through competition even after approval.